---
title: "JINLING PHARM. branch received the acceptance notice for Olaratumab tablets"
description: "JINLING PHARM.'s subsidiary Nanjing JINLING Pharmaceutical Factory recently received the acceptance notice from the National Medical Products Administration for the application of domestic production "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/245653854.md"
published_at: "2025-06-23T08:43:02.000Z"
---

# JINLING PHARM. branch received the acceptance notice for Olaratumab tablets

> JINLING PHARM.'s subsidiary Nanjing JINLING Pharmaceutical Factory recently received the acceptance notice from the National Medical Products Administration for the application of domestic production drug registration clinical trials for Elagolix tablets. Elagolix is a GnRH antagonist that was approved by the FDA in 2018, specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials go smoothly, it will enhance the company's product line and competitiveness

According to the Zhitong Finance APP, JINLING PHARM. (000919.SZ) announced that its subsidiary, Nanjing JINLING Pharmaceutical Factory, recently received the acceptance notice from the National Medical Products Administration for the application of Olaragolix tablets (CYHL2500117, CYHL2500118), which pertains to the registration of clinical trials for domestically produced drugs.

Olaragolix is an oral gonadotropin-releasing hormone (GnRH) antagonist that was approved by the FDA for marketing on July 23, 2018. It is the first oral GnRH receptor antagonist approved specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials for this product progress smoothly, it will enrich and enhance the company's product line layout and improve the competitiveness of the company's products

### Related Stocks

- [000919.CN - JINLING PHARM.](https://longbridge.com/en/quote/000919.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| New study finds early hormone replacement therapy reduces risk of osteoporosis and fractures for older women | A new study presented at the 2026 AAOS Annual Meeting reveals that early hormone replacement therapy (HRT) significantly | [Link](https://longbridge.com/en/news/277412093.md) |
| SSY Group's Respiratory Drug Approved for Production in China | SSY Group's Respiratory Drug Approved for Production in China | [Link](https://longbridge.com/en/news/277561555.md) |
| How can I systematically track high-win-rate wallet addresses on Polymarket? | The article discusses strategies for tracking high-win-rate wallet addresses on Polymarket, emphasizing the importance o | [Link](https://longbridge.com/en/news/277561416.md) |
| LESS NOISE, BETTER SIGNALS: HOW PHARMA CAN MEASURE IMPACT AS AI RESHAPES SEARCH | The article discusses the transformation of search in the pharmaceutical industry due to AI adoption, emphasizing the sh | [Link](https://longbridge.com/en/news/277470520.md) |
| Does RFK Jr. care that babies will needlessly die under his vaccination policies? | The article discusses the impact of Robert F. Kennedy Jr.'s vaccination policies, highlighting a resurgence of measles c | [Link](https://longbridge.com/en/news/277225914.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.